# Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab

> **NCT06796114** · NA · RECRUITING · sponsor: **Centre Hospitalier Universitaire de Besancon** · enrollment: 120 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **OTHER:** blood sample

## Key facts

- **NCT ID:** NCT06796114
- **Lead sponsor:** Centre Hospitalier Universitaire de Besancon
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-25
- **Primary completion:** 2027-06-25
- **Final completion:** 2030-01-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06796114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06796114, "Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06796114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*